These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36698790)

  • 1. Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders.
    Buffa V; Alvarez Vargas JR; Galy A; Spinozzi S; Rocca CJ
    Front Genome Ed; 2022; 4():997142. PubMed ID: 36698790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells.
    Salisbury-Ruf CT; Larochelle A
    J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.
    Yu KR; Natanson H; Dunbar CE
    Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.
    Lee BC; Lozano RJ; Dunbar CE
    Mol Ther; 2021 Nov; 29(11):3205-3218. PubMed ID: 34509667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Editing in Hematopoietic Stem Cells.
    Liao J; Wu Y
    Adv Exp Med Biol; 2023; 1442():177-199. PubMed ID: 38228965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA.
    Quintana-Bustamante O; Fañanas-Baquero S; Orman I; Torres R; Duchateau P; Poirot L; Gouble A; Bueren JA; Segovia JC
    PLoS One; 2019; 14(10):e0223775. PubMed ID: 31618280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
    Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
    Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Curative DNA Code for Hematopoietic Defects: Novel Cell Therapies for Monogenic Diseases of the Blood and Immune System.
    Porteus MH; Pavel-Dinu M; Pai SY
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):647-665. PubMed ID: 35773054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for
    Dudek AM; Porteus MH
    Front Immunol; 2021; 12():660302. PubMed ID: 34122418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
    Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
    J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
    Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved medium formulation for efficient
    Rai R; Naseem A; Vetharoy W; Steinberg Z; Thrasher AJ; Santilli G; Cavazza A
    Mol Ther Methods Clin Dev; 2023 Jun; 29():58-69. PubMed ID: 36950452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.
    Tucci F; Scaramuzza S; Aiuti A; Mortellaro A
    Mol Ther; 2021 Feb; 29(2):489-504. PubMed ID: 33221437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells.
    Peterson CW; Venkataraman R; Reddy SS; Pande D; Enstrom MR; Radtke S; Humbert O; Kiem HP
    Mol Ther Methods Clin Dev; 2022 Mar; 24():30-39. PubMed ID: 34977270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates.
    Petty NE; Radtke S; Fields E; Humbert O; Llewellyn MJ; Laszlo GS; Zhu H; Jerome KR; Walter RB; Kiem HP
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101121. PubMed ID: 37868209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins.
    Pavani G; Laurent M; Fabiano A; Cantelli E; Sakkal A; Corre G; Lenting PJ; Concordet JP; Toueille M; Miccio A; Amendola M
    Nat Commun; 2020 Jul; 11(1):3778. PubMed ID: 32728076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.
    Dever DP; Porteus MH
    Curr Opin Hematol; 2017 Nov; 24(6):481-488. PubMed ID: 28806273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy and gene editing strategies in inherited blood disorders.
    Song X; Liu J; Chen T; Zheng T; Wang X; Guo X
    J Genet Genomics; 2024 Jul; ():. PubMed ID: 38986807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases.
    Cruz LJ; Rezaei S; Grosveld F; Philipsen S; Eich C
    Front Genome Ed; 2022; 4():1030285. PubMed ID: 36407494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.